Incyte announced that the European Commission approved its drug Zynyz (retifanlimab) for first‑line treatment of advanced squamous cell carcinoma of the anal canal (SCAC) on March 06 2026, allowing the drug to be marketed in the European Union as a new systemic therapy for this rare but aggressive cancer.
Zynyz is a programmed death‑1 (PD‑1) inhibitor that, when combined with carboplatin and paclitaxel, became the first approved regimen for adult SCAC patients in Europe. The approval follows the Phase 3 POD1UM‑303/InterAACT2 trial, which demonstrated a 37% reduction in the risk of progression or death and improved progression‑free survival of 9.3 months versus 7.4 months compared with chemotherapy alone.
The approval expands Incyte’s oncology footprint in the EU and provides a new revenue stream for a drug that has already been approved in the United States. It also strengthens the company’s pipeline positioning ahead of the 2028 Jakafi patent cliff, offering a potential high‑margin product in a niche market.
Bill Meury, President and Chief Executive Officer of Incyte, said the EC approval “marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades.” He added that the approval “helps expand the standard‑of‑care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.”
The approval is significant because SCAC accounts for about 85% of anal cancers worldwide, is a rare disease with an estimated incidence of 1–2 cases per 100,000 people, and is increasing by roughly 3% annually. About 90% of cases are associated with human papillomavirus (HPV) infection, and the disease often presents with symptoms that overlap with less serious conditions, leading to delayed diagnosis.
Incyte’s strategy to diversify revenue ahead of the Jakafi patent cliff is reinforced by this approval. Zynyz’s niche market position and high‑margin potential provide a counterbalance to the expected generic competition for Jakafi, which is projected to enter the market in late 2028 or early 2029. The company continues to advance other pipeline assets, positioning itself for sustained growth in oncology.
The approval also places Incyt in a competitive landscape where other PD‑1 inhibitors, such as Merck’s Keytruda, are used off‑label for anal cancer. Zynyz’s first‑in‑class status as a systemic therapy in Europe gives Incyte a distinct advantage in a market with limited approved options.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.